Great Valley Advisor Group Inc. Has $16.29 Million Stake in AbbVie Inc. $ABBV

Great Valley Advisor Group Inc. decreased its stake in AbbVie Inc. (NYSE:ABBV) by 4.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 71,310 shares of the company’s stock after selling 3,462 shares during the quarter. Great Valley Advisor Group Inc.’s holdings in AbbVie were worth $16,293,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of ABBV. Brighton Jones LLC increased its holdings in shares of AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. increased its holdings in shares of AbbVie by 5.0% in the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after acquiring an additional 789 shares in the last quarter. Ieq Capital LLC increased its holdings in shares of AbbVie by 4.6% in the second quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after acquiring an additional 5,274 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC increased its holdings in shares of AbbVie by 117.3% in the second quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock worth $210,685,000 after acquiring an additional 612,702 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on ABBV. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Monday. Royal Bank Of Canada assumed coverage on AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective for the company. Bank of America upgraded AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective for the company in a report on Thursday, April 30th. Morgan Stanley raised their price target on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Finally, Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, June 7th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $253.43.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts and media coverage highlighted AbbVie’s Skyrizi and Rinvoq as key growth drivers, noting strong first-quarter performance and the potential for continued sales momentum through 2026, including additional indications. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Positive Sentiment: Another market commentary framed AbbVie as a growth-pharma stock at a value-pharma price, reinforcing the view that its earnings growth and pipeline may justify the valuation. AbbVie: Growth-Pharma Profile At A Value-Pharma Price
• Positive Sentiment: AbbVie was also featured on CNBC’s “Final Trades”, which can support investor sentiment by keeping the stock in the market spotlight. AbbVie, Devon Energy and more on CNBC’s ‘Final Trades’
• Neutral Sentiment: Several pieces described AbbVie as a stock worth watching or holding after a strong run, with valuation and balance-sheet concerns tempering enthusiasm but not signaling a major change in the business outlook. Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225
• Negative Sentiment: AbbVie also faced a FDA Complete Response Letter for its fast-acting neurotoxin TrenibotE, citing manufacturing-related issues. While the letter reportedly raised no safety or efficacy concerns, it delays the program and adds near-term regulatory uncertainty. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Trading Up 0.0%

NYSE:ABBV opened at $225.04 on Friday. The stock has a market cap of $397.60 billion, a P/E ratio of 110.86, a PEG ratio of 0.69 and a beta of 0.32. The stock has a 50 day simple moving average of $210.80 and a 200 day simple moving average of $219.01. AbbVie Inc. has a 1-year low of $181.73 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. The business had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period last year, the firm posted $2.46 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 14.3 EPS for the current year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.